Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184


Inhibition of autophagy stimulate molecular iodine-induced apoptosis in hormone independent breast tumors.

Singh P, Godbole M, Rao G, Annarao S, Mitra K, Roy R, Ingle A, Agarwal G, Tiwari S.

Biochem Biophys Res Commun. 2011 Nov 11;415(1):181-6. doi: 10.1016/j.bbrc.2011.10.054. Epub 2011 Oct 18.


Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models.

Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu Y, Ravoori M, Kundra V, Ajani J, Lee JS, Ki Hong W, Mills GB.

Mol Cancer Ther. 2011 Dec;10(12):2350-62. doi: 10.1158/1535-7163.MCT-11-0497. Epub 2011 Oct 12.


Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach.

Reka AK, Kuick R, Kurapati H, Standiford TJ, Omenn GS, Keshamouni VG.

J Thorac Oncol. 2011 Nov;6(11):1784-92. doi: 10.1097/JTO.0b013e31822adfb0.


FOXA1: master of steroid receptor function in cancer.

Augello MA, Hickey TE, Knudsen KE.

EMBO J. 2011 Sep 20;30(19):3885-94. doi: 10.1038/emboj.2011.340. Review.


An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells.

Yao F, Wang G, Wei W, Tu Y, Tong H, Sun S.

Mol Med Rep. 2012 Jan;5(1):84-8. doi: 10.3892/mmr.2011.590. Epub 2011 Sep 19.


Hsp90 and client protein maturation.

Wayne N, Mishra P, Bolon DN.

Methods Mol Biol. 2011;787:33-44. doi: 10.1007/978-1-61779-295-3_3.


Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53.

Hagn F, Lagleder S, Retzlaff M, Rohrberg J, Demmer O, Richter K, Buchner J, Kessler H.

Nat Struct Mol Biol. 2011 Sep 4;18(10):1086-93. doi: 10.1038/nsmb.2114.


Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.

Khong T, Spencer A.

Mol Cancer Ther. 2011 Oct;10(10):1909-17. doi: 10.1158/1535-7163.MCT-11-0174. Epub 2011 Aug 22.


The 'active life' of Hsp90 complexes.

Prodromou C.

Biochim Biophys Acta. 2012 Mar;1823(3):614-23. doi: 10.1016/j.bbamcr.2011.07.020. Epub 2011 Aug 4. Review.


Treatment of doxorubicin-resistant MCF7/Dx cells with nitric oxide causes histone glutathionylation and reversal of drug resistance.

de Luca A, Moroni N, Serafino A, Primavera A, Pastore A, Pedersen JZ, Petruzzelli R, Farrace MG, Pierimarchi P, Moroni G, Federici G, Sinibaldi Vallebona P, Lo Bello M.

Biochem J. 2011 Dec 1;440(2):175-83. doi: 10.1042/BJ20111333.


An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.

Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Fellmann C, Taylor MJ, Weissenboeck M, Graeber TG, Kogan SC, Vakoc CR, Lowe SW.

Genes Dev. 2011 Aug 1;25(15):1628-40. doi: 10.1101/gad.17269211. Erratum in: Genes Dev. 2011 Sep 15;25(18):1997. Fellman, Christof [corrected to Fellmann, Christof].


Taking a "good" look at free radicals in the aging process.

Hekimi S, Lapointe J, Wen Y.

Trends Cell Biol. 2011 Oct;21(10):569-76. doi: 10.1016/j.tcb.2011.06.008. Epub 2011 Aug 6. Review.


[Gene RAD31 is identical to gene MEC1 of yeast Saccharomyces cerevisiae].

Kozhina TN, Kozhin SA, Korolev VG.

Genetika. 2011 May;47(5):610-4. Russian.


Calcium/calmodulin kinase1 and its relation to thermotolerance and HSP90 in Sporothrix schenckii: an RNAi and yeast two-hybrid study.

Rodriguez-Caban J, Gonzalez-Velazquez W, Perez-Sanchez L, Gonzalez-Mendez R, Rodriguez-del Valle N.

BMC Microbiol. 2011 Jul 11;11:162. doi: 10.1186/1471-2180-11-162.


Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.

Oikonomou E, Koc M, Sourkova V, Andera L, Pintzas A.

PLoS One. 2011;6(6):e21632. doi: 10.1371/journal.pone.0021632. Epub 2011 Jun 27.


Associations of HSP90 client proteins in human breast cancer.

Shipp C, Watson K, Jones GL.

Anticancer Res. 2011 Jun;31(6):2095-101.


Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention.

Athar M, Kopelovich L.

Cancer Prev Res (Phila). 2011 Jul;4(7):957-61. doi: 10.1158/1940-6207.CAPR-11-0266.


Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.

Mehta PP, Whalen P, Baxi SM, Kung PP, Yamazaki S, Yin MJ.

Clin Cancer Res. 2011 Aug 15;17(16):5432-42. doi: 10.1158/1078-0432.CCR-11-0592. Epub 2011 Jun 29. Retraction in: Clin Cancer Res. 2017 Jan 15;23 (2):612.


Detection of changes in gene regulatory patterns, elicited by perturbations of the Hsp90 molecular chaperone complex, by visualizing multiple experiments with an animation.

Echeverría PC, Forafonov F, Pandey DP, Mühlebach G, Picard D.

BioData Min. 2011 Jun 14;4(1):15. doi: 10.1186/1756-0381-4-15.


SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.

Li D, Marchenko ND, Moll UM.

Cell Death Differ. 2011 Dec;18(12):1904-13. doi: 10.1038/cdd.2011.71. Epub 2011 Jun 3.

Supplemental Content

Support Center